Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Are seniors getting the right dose? new study checks blood thinner use in atrial fibrillation

NCT ID NCT07242326

Knowledge-focused Sponsor: Kotyora Family Medicine Health Management and Education Association Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 1,000 adults aged 65 and older with atrial fibrillation who take blood thinners. Researchers will check if the doses match official guidelines and how consistently patients take their medication. The goal is to identify unsafe practices and refer patients to heart specialists when needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged ≥65 years with established atrial fibrillation (any type) receiving care in family health centers across Ordu, Türkiye. The prospective cohort enrolls consecutive eligible attendees during Dec 1, 2025-May 31, 2026 at a single routine visit; the retrospective cohort includes patients with AF who received an oral anticoagulant during Dec 15, 2025-May 31, 2026 identified from primary care records. Exclusions: mechanical prosthetic heart valve or moderate-severe rheumatic mitral stenosis, and cases lacking the minimal data needed for dose/adherence classification. No investigational treatment is delivered; care is routine with same-day tertiary referral when unsafe dosing, high-risk drug interactions, or very low renal function are detected.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥65 years. * Established atrial fibrillation (any type) documented in the medical record. * Presenting to a family health center (primary care) in Ordu province during the prospective window or having records within the retrospective window. * On an oral anticoagulant (DOAC) at any time in the 12-month window. Exclusion Criteria: * Mechanical prosthetic heart valve or moderate-to-severe rheumatic mitral stenosis * Participation in an interventional drug study affecting anticoagulation * Lack of minimal data elements required for dose classification (age, sex, body weight, serum creatinine with date, current OAC and regimen) * Investigator judgment that reliable data cannot be obtained from records

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Direct oral anticoagulants (doacs) Medication adherence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ordu University Faculty of Medicine, Department of Cardiology

    Ordu, Ordu, 52200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.